Tirzepatide Research Information
GLP-1 / GIP Receptor Agonist
Dual Hormone Receptor Agonist for Metabolic Research
️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
Contents
What is Tirzepatide?
Tirzepatide is a dual GLP-1 and GIP receptor agonist that mimics the action of two naturally occurring hormones involved in metabolic regulation. It is a 39-amino acid peptide with a C20 fatty acid side chain that extends its half-life.
Unlike semaglutide which targets only GLP-1, tirzepatide targets both GLP-1 and GIP receptors, making it a dual-agonist approach for appetite regulation and glycemic control.
How Tirzepatide Works
Tirzepatide works by mimicking two naturally occurring hormones that regulate appetite, blood sugar, and energy balance:
GLP-1
Reduces appetite, slows digestion, enhances insulin secretion
GIP
Improves insulin sensitivity, supports metabolic health
Glucagon
Increases energy expenditure, promotes fat metabolism
Combined, these mechanisms promote reduced food intake, improved insulin response, and increased calorie burning.
Research Applications
Tirzepatide has been studied across multiple clinical trials, with research focusing on:
Obesity & Weight Management
Evaluated for weight reduction in individuals with obesity or overweight
Type 2 Diabetes
Assessed for glycemic control (HbA1c reduction) in type 2 diabetes
Cardiometabolic Health
Significant improvements in blood pressure, lipids, waist circumference, and liver fat
Metabolic Research
Investigating effects on metabolic dysfunction-associated steatotic liver disease (MASLD), osteoarthritis, and sleep apnea
Clinical Studies
SURMOUNT Trials (Weight Management)
The SURMOUNT clinical trial program evaluated tirzepatide for weight management:
| Trial | Duration | Weight Loss (15mg) | Weight Loss (Placebo) |
|---|---|---|---|
| SURMOUNT-1 | 72 weeks | −20.9% | −3.1% |
| SURMOUNT-2 | 72 weeks | −15.7% | −3.3% |
| SURMOUNT-3 | 72 weeks | −18.4% | −3.5% |
Key finding: At the 15 mg dose, participants lost an average of 20.9% of their body weight after 72 weeks.
Interactive Dosing Guide
Select your pen size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per pen:
️ Step 1: Select Your Pen Size
Step 2: Select Your Dose
Pen Size
30mg Pen
Selected Dose
2.5 mg
Doses per Pen
12 doses
Pen Clicks
25 clicks
Volume
0.25 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Once weekly - Once weekly - Loading Phase (Weeks 1-4)
️ Do not change your dose unless advised by a qualified professional.
Vial Users (Insulin Syringe)
Select your vial size to see the units on an insulin syringe (all vials use 3mL bac water):
Vial Size
30mg vial with 3mL bac water
| Dose | Units on Syringe | Volume (mL) | Protocol Level |
|---|---|---|---|
| 2.5 mg | 25 units | 0.25 mL | Level 1 |
| 5 mg | 50 units | 0.50 mL | Level 2 |
| 7.5 mg | 75 units | 0.75 mL | Level 3 |
| 10 mg | 100 units | 1.00 mL | Level 4 |
| 15 mg | 150 units | 1.50 mL | Level 5 |
️ Always use a new sterile needle and syringe for each injection.
️ Safety & Precautions
Do not use if you:
- Are allergic to tirzepatide or any ingredients
- Have type 1 diabetes
- Are pregnant or breastfeeding
Common side effects:
- Nausea (usually improves over time)
- Diarrhoea (usually improves over time)
- Vomiting
- Low blood sugar (if used with other anti-diabetic medication)
- Stomach pain, indigestion, constipation
- Decreased appetite, weight loss
️ Warning: If you experience severe and ongoing stomach pain, difficulty breathing, or signs of a severe allergic reaction, seek immediate medical help.
References
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. (SURMOUNT-1)
- Garvey WT, et al. "Tirzepatide in Patients with Type 2 Diabetes and Obesity." The Lancet. 2023;401:109-121. (SURPASS-2)
- ClinicalTrials.gov. "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight." NCT04184622.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026